Cancer disrupts the delicate balance within the blood. Apheresis and intravenous methylprednisolone (IVMP) are two therapies that target this imbalance, each with distinct roles in the fight against cancer. This review delves into the mechanisms, applications, and potential benefits of both Apheresis and IVMP in cancer treatment. We explore their use in specific scenarios like managing autoimmune complications, collecting stem cells for transplants, and even paving the way for advanced immunotherapies.
The human body's battlefield against cancer often extends to the blood. Cancer cells can release harmful substances or disrupt the immune system's ability to fight them. This is where Apheresis and IVMP come in, offering targeted approaches to manipulate the blood composition and bolster the body's defenses.
Apheresis, also known as therapeutic plasma exchange, is a procedure that selectively removes specific components from the blood. Similar to dialysis for kidney function, Apheresis acts as a filtration system:
Mechanism: Blood is drawn from the patient, passed through a machine that separates desired components, and then the remaining blood is returned to the body.
Applications in Cancer:
Managing Autoimmune Complications: Apheresis can remove harmful antibodies that attack healthy tissues in conditions like paraneoplastic pemphigus, a rare skin blistering disease associated with some cancers.
Collecting Stem Cells for Transplants: Apheresis is used to collect stem cells from a patient's blood for subsequent transplantation, a crucial step in some cancer treatments like high-dose chemotherapy.
Preparing for Advanced Immunotherapies: Apheresis can help prepare patients for CAR-T cell therapy by removing T cells that could hinder the effectiveness of the engineered CAR-T cells.
Intravenous methylprednisolone (IVMP) is a powerful corticosteroid medication administered directly into the bloodstream. While not a filtration technique like Apheresis, IVMP offers distinct benefits:
Mechanism: IVMP acts as an immunosuppressant, reducing inflammation caused by the immune system's overactivity in certain situations.
Applications in Cancer:
Reducing Inflammation from Tumor Lysis Syndrome: Rapid destruction of cancer cells, sometimes caused by chemotherapy, can trigger an inflammatory response. IVMP can help manage this reaction.
Suppression of Graft-versus-Host Disease (GVHD): In stem cell transplants using cells from a donor, GVHD can occur when the donor's immune system attacks the recipient's body. IVMP can help suppress this reaction.
Managing Autoimmune Complications: Similar to Apheresis, IVMP can be used to manage autoimmune complications associated with some cancers.
Apheresis and IVMP serve distinct purposes in cancer treatment. Choosing the right approach depends on the specific needs of the patient and the type of cancer. In some cases, both therapies may be used in conjunction with other cancer treatments.
Apheresis and IVMP are valuable tools in the fight against cancer. By understanding their unique mechanisms and applications, healthcare professionals can personalize treatment plans, optimize patient outcomes, and ultimately improve the lives of cancer patients. Further research remains crucial to explore the full potential of these therapies in combination with other advancements in cancer treatment.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?
2.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
3.
Weight loss trial reports success for breast cancer patients at one year mark
4.
Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC
5.
Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients
1.
Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers
2.
Single-Cell Lineage Tracing in Hematology: Decoding the Cellular Blueprint of Blood Disorders
3.
AI-Powered Strategies for Precision and Improved Outcomes in Esophageal Cancer, a Global Health Crisis
4.
Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential
5.
Epigenetic Subtyping of Complex Hematologic Disorders
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Updates on the First Line Management of ALK+ NSCLC
2.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
3.
Navigating the Complexities of Ph Negative ALL - Part V
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation